Neil Gallagher

Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an lhrh analogue and/or a bisphosphonate

Pre-clinical and early clinical activity of the highly selective, orally available, dual Src/Abl kinase inhibitor AZD0530

Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and a biphosphonate

Combinaison comprenant un n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulfonamide et un analogue de la lhrh et/ou un bisphosphonate

Kombination aus n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-ä1,3,4-oxadiazol-2-ylüphenyl)pyridin-3-sulfonamid und einem biphosphonat Combination of N- (3-methoxy-5-methylpyrazin-2-yl) -2- (4-ä1,3,4-oxadiazol-2-ylüphenyl) pyridine-3-sulfonamide and a bisphosphonate

KOMBINATION AUS N-(3-METHOXY-5-METHYLPYRAZIN-2- YL)-2-(4-Ä1,3,4-OXADIAZOL-2-YLÜPHENYL)PYRIDIN-3 SULFONAMID UND EINEM BIPHOSPHONAT

Combinaison a base de n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulfonamide et d'un bisphosphonate

Combination of N- (3-methoxy-5-methylpyrazin-2-yl) -2- (4-ä1,3,4-oxadiazol-2-ylüphenyl) pyridine-3-sulfonamide and a bisphosphonate

Kombination aus n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulfonamid und einem lhrh-analogon und/oder einem bisphosphonat

Combinacion que comprende n-(3-metoxi-5-metilpirazin-2-il)-2-(4-(1,3,4-oxadiazol-2-il)fenil)piridina-3-sulfonamida y un bifosfonato.